BRPI0915130A2 - derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c - Google Patents

derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c

Info

Publication number
BRPI0915130A2
BRPI0915130A2 BRPI0915130A BRPI0915130A BRPI0915130A2 BR PI0915130 A2 BRPI0915130 A2 BR PI0915130A2 BR PI0915130 A BRPI0915130 A BR PI0915130A BR PI0915130 A BRPI0915130 A BR PI0915130A BR PI0915130 A2 BRPI0915130 A2 BR PI0915130A2
Authority
BR
Brazil
Prior art keywords
benzapine
indole
hepatitis
treatment
carboxylic acid
Prior art date
Application number
BRPI0915130A
Other languages
English (en)
Inventor
W. Martin Scott
P. Bergstrom Carl
Ding Min
Zheng Xiaofan
G. Gentles Robert
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915130(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BRPI0915130A2 publication Critical patent/BRPI0915130A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0915130A 2008-05-06 2009-05-05 derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c BRPI0915130A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06
PCT/US2009/042805 WO2009137454A1 (en) 2008-05-06 2009-05-05 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
BRPI0915130A2 true BRPI0915130A2 (pt) 2019-09-24

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915130A BRPI0915130A2 (pt) 2008-05-06 2009-05-05 derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c

Country Status (19)

Country Link
US (1) US8133884B2 (pt)
EP (1) EP2280975B1 (pt)
JP (1) JP2011520810A (pt)
KR (1) KR20110015588A (pt)
CN (1) CN102083834A (pt)
AR (1) AR071684A1 (pt)
AU (1) AU2009244409A1 (pt)
BR (1) BRPI0915130A2 (pt)
CA (1) CA2723683A1 (pt)
CL (1) CL2009001089A1 (pt)
CO (1) CO6290645A2 (pt)
EA (1) EA201001748A1 (pt)
IL (1) IL208753A0 (pt)
MX (1) MX2010011921A (pt)
NZ (1) NZ588556A (pt)
PE (1) PE20091879A1 (pt)
TW (1) TW200951135A (pt)
WO (1) WO2009137454A1 (pt)
ZA (1) ZA201007649B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN106986862A (zh) 2010-12-22 2017-07-28 Abbvie 公司 丙型肝炎抑制剂及其用途
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
IN2014MN01547A (pt) 2012-02-10 2015-05-08 Lupin Ltd
CA2879398A1 (en) * 2012-07-18 2014-01-23 Bristol-Myers Squibb Holdings Ireland Unlimited Company Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ES2343914T3 (es) * 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Also Published As

Publication number Publication date
AU2009244409A1 (en) 2009-11-12
NZ588556A (en) 2012-06-29
CA2723683A1 (en) 2009-11-12
IL208753A0 (en) 2010-12-30
WO2009137454A1 (en) 2009-11-12
MX2010011921A (es) 2010-11-30
JP2011520810A (ja) 2011-07-21
US8133884B2 (en) 2012-03-13
AR071684A1 (es) 2010-07-07
CO6290645A2 (es) 2011-06-20
EP2280975B1 (en) 2014-01-01
US20090280083A1 (en) 2009-11-12
EA201001748A1 (ru) 2011-06-30
TW200951135A (en) 2009-12-16
EP2280975A1 (en) 2011-02-09
CN102083834A (zh) 2011-06-01
PE20091879A1 (es) 2009-12-19
ZA201007649B (en) 2012-04-25
CL2009001089A1 (es) 2011-04-29
KR20110015588A (ko) 2011-02-16

Similar Documents

Publication Publication Date Title
CY2020032I2 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
CY2018030I2 (el) Φαρμακοτεχνικη μορφη 514
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
EP2233474A4 (en) CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
EP2291078A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
EP2144635A4 (en) STERILIZING COMPOSITION
ZA201007649B (en) 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
DK2271321T3 (da) Farmaceutisk sammensætning 271
IT1391108B1 (it) Processo per la preparazione di etilidennorbornene.
ITPD20080001U1 (it) "stendibiancheria perfezionato"
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
EP2358198A4 (en) HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DK2241564T3 (da) 3,8-diaminotetrahydroquinolin-derivat
ITRM20080037A1 (it) Procedimento per la ultrapurificazione di alginati.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.